Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 5
1985 8
1986 49
1987 25
1988 13
1989 15
1990 46
1991 16
1992 21
1993 22
1994 34
1995 29
1996 30
1997 30
1998 38
1999 50
2000 56
2001 59
2002 56
2003 61
2004 48
2005 48
2006 52
2007 61
2008 53
2009 70
2010 72
2011 59
2012 79
2013 80
2014 83
2015 97
2016 102
2017 85
2018 77
2019 87
2020 102
2021 129
2022 110
2023 104
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

2,110 results

Results by year

Filters applied: . Clear all
Page 1
Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, Erlinge D, Hallen O, Held C, Hjalmarsson P, Johansson P, Karlström P, Kellerth T, Marandi T, Ravn-Fischer A, Sundström J, Östlund O, Hofmann R, Jernberg T; REDUCE-AMI Investigators. Yndigegn T, et al. N Engl J Med. 2024 Apr 18;390(15):1372-1381. doi: 10.1056/NEJMoa2401479. Epub 2024 Apr 7. N Engl J Med. 2024. PMID: 38587241 Clinical Trial.
METHODS: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients with an acute myocardial infarction who had undergone coronary angiography and had a left ventricular ejection fraction of at least 50% to rec …
METHODS: In a parallel-group, open-label trial performed at 45 centers in Sweden, Estonia, and New Zealand, we randomly assigned patients wi …
Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review.
Muresan L, Cismaru G, Muresan C, Rosu R, Gusetu G, Puiu M, Mada RO, Martins RP. Muresan L, et al. Ann Pharm Fr. 2022 Sep;80(5):617-634. doi: 10.1016/j.pharma.2022.01.007. Epub 2022 Jan 31. Ann Pharm Fr. 2022. PMID: 35093388 Free article. Review.
The aim of this study was to analyze the current existing evidence for bisoprolol for the treatment of both supraventricular and ventricular arrhythmias. MATERIAL AND METHODS: Using the keywords "bisoprolol" and "arrhythmias" or "atrial fibrillation" or "ventricular …
The aim of this study was to analyze the current existing evidence for bisoprolol for the treatment of both supraventricular and vent …
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.
Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, Haynes S, Calvert MJ, Deeks JJ, Steeds RP, Strauss VY, Rahimi K, Camm AJ, Griffith M, Lip GYH, Townend JN, Kirchhof P; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Kotecha D, et al. JAMA. 2020 Dec 22;324(24):2497-2508. doi: 10.1001/jama.2020.23138. JAMA. 2020. PMID: 33351042 Free PMC article. Clinical Trial.
INTERVENTIONS: Digoxin (n = 80; dose range, 62.5-250 mug/d; mean dose, 161 mug/d) or bisoprolol (n = 80; dose range, 1.25-15 mg/d; mean dose, 3.2 mg/d). ...Adverse events were less common with digoxin; 20 patients (25%) in the digoxin group had at least 1 AE vs 51 patients …
INTERVENTIONS: Digoxin (n = 80; dose range, 62.5-250 mug/d; mean dose, 161 mug/d) or bisoprolol (n = 80; dose range, 1.25-15 mg/d; me …
Therapeutic Properties of Highly Selective beta-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
AlHabeeb W, Mrabeti S, Abdelsalam AAI. AlHabeeb W, et al. Cardiovasc Drugs Ther. 2022 Oct;36(5):959-971. doi: 10.1007/s10557-021-07205-y. Epub 2021 Jun 9. Cardiovasc Drugs Ther. 2022. PMID: 34106365 Free PMC article. Review.
Bisoprolol and nebivolol are highly selective beta(1)-adrenoceptor antagonists, with clinical indications in many countries within the management of heart failure with reduced left ventricular ejection fraction (HFrEF), ischaemic heart disease (IHD), and hypertension. ...I
Bisoprolol and nebivolol are highly selective beta(1)-adrenoceptor antagonists, with clinical indications in many countries within th
Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).
Cotton S, Devereux G, Abbas H, Briggs A, Campbell K, Chaudhuri R, Choudhury G, Dawson D, De Soyza A, Fielding S, Gompertz S, Haughney J, Lang CC, Lee AJ, MacLennan G, MacNee W, McCormack K, McMeekin N, Mills NL, Morice A, Norrie J, Petrie MC, Price D, Short P, Vestbo J, Walker P, Wedzicha J, Wilson A, Lipworth BJ. Cotton S, et al. Trials. 2022 Apr 14;23(1):307. doi: 10.1186/s13063-022-06226-8. Trials. 2022. PMID: 35422024 Free PMC article. Clinical Trial.
Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. The bisoprolol in COPD study (BICS) investigates whether adding bisoprolol to routine COPD treatment has clinical and cost-ef …
Observational studies consistently report that beta blocker use in people with COPD is associated with a reduced risk of COPD exacerbations. …
Bisoprolol: A comprehensive profile.
Bakheit AH, Ali R, Alshahrani AD, El-Azab AS. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:51-89. doi: 10.1016/bs.podrm.2020.07.006. Epub 2020 Sep 8. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461700
The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appearance, its uses, applications, and methods for the preparation are outlined. ...The mass fragmentation pattern of bisoprolol fumarat …
The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appe …
Beta-blockade and surgery.
Prichard BN, Robin JM. Prichard BN, et al. Eur Heart J. 2001 Aug;22(15):1253-5. doi: 10.1053/euhj.2000.2768. Eur Heart J. 2001. PMID: 11465960 No abstract available.
Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine.
Gottwald-Hostalek U, Sun N, Barho C, Hildemann S. Gottwald-Hostalek U, et al. Clin Pharmacol Drug Dev. 2017 Jan;6(1):9-18. doi: 10.1002/cpdd.309. Epub 2016 Oct 26. Clin Pharmacol Drug Dev. 2017. PMID: 27653022
Among combinations of hypertension medications, a beta-blocker such as bisoprolol with a calcium channel blocker such as amlodipine is an effective combination therapy for hypertension, with distinct and complimentary modes of action. With advantages over free-dose combina …
Among combinations of hypertension medications, a beta-blocker such as bisoprolol with a calcium channel blocker such as amlodipine i …
Pharmacogenetic polymorphisms affecting bisoprolol response.
Castaño-Amores C, Díaz-Villamarín X, Pérez-Gutiérrez AM, Antúnez-Rodríguez A, Pozo-Agundo A, Moreno-Escobar E, Sánchez-Ramos JG, Martínez-González LJ, Dávila-Fajardo CL. Castaño-Amores C, et al. Biomed Pharmacother. 2021 Oct;142:112069. doi: 10.1016/j.biopha.2021.112069. Epub 2021 Aug 27. Biomed Pharmacother. 2021. PMID: 34470728 Free article.
The ADRB1 Arg389Gly (rs1801253) was the most studied genetic polymorphism and it seems to influence the response to bisoprolol, although studies are inconclusive. Even, we performed a meta-analysis about its influence on systolic/diastolic blood pressure in patients treate …
The ADRB1 Arg389Gly (rs1801253) was the most studied genetic polymorphism and it seems to influence the response to bisoprolol, altho …
Efficacy and Safety of Bisoprolol in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
Feng Z, Zhang L, Wang Y, Guo H, Liu J. Feng Z, et al. Int J Chron Obstruct Pulmon Dis. 2023 Dec 23;18:3067-3083. doi: 10.2147/COPD.S438930. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 38152590 Free PMC article.
PURPOSE: To evaluate the clinical efficacy and safety of bisoprolol in patients with chronic obstructive pulmonary disease (COPD). ...The effect of bisoprolol on 6MWD in COPD patients, MD (1.37 [95% CI, 1.08 to 1.66], P=0.000), which showed a statistically significa …
PURPOSE: To evaluate the clinical efficacy and safety of bisoprolol in patients with chronic obstructive pulmonary disease (COPD). .. …
2,110 results